NY-SECURITYSCORECARD
18.1.2023 08:01:36 CET | Business Wire | Press release
SecurityScorecard, the global leader in cybersecurity ratings, today announced the results of its new report, Addressing the Trust Deficit In Critical Infrastructure, which revealed 48% of critical manufacturing organizations ranked “C,” “D,” or “F” on SecurityScorecard’s security ratings platform. Published during the World Economic Forum (WEF) Annual Meeting, the report analyzed the current state of cyber resilience in the critical infrastructure sectors such as Energy, Chemical, Healthcare, and others, as designated by the Cybersecurity and Infrastructure Security Agency (CISA). Organizations with an “A” security rating are 7.7 times less likely to sustain a breach than those with an “F” rating.
“Security ratings are a trusted barometer of cyber resilience and the time is now for policymakers and organizations to make cyber risk measurement mandatory,” said Aleksandr Yampolskiy, co-founder and CEO of SecurityScorecard. “Cyberattacks in the last 10 years have gotten much worse, more complex, and increasingly have targeted critical infrastructure, thereby undermining the public’s trust in the cyber resilience of our global economy.”
SecurityScorecard provides comprehensive security ratings, automated assessments, and guidance from industry experts, providing a patented and easy-to-understand A-F graded scorecards for improved communication, effective compliance reporting, and more informed decision-making.
According to the World Economic Forum, only 19% of cyber leaders feel confident that their organizations are cyber resilient. SecurityScorecard recently joined the World Economic Forum Global Innovators Community, contributing to WEF’s Centre for Cybersecurity’s initiative to address systemic challenges, improve trust, and build cyber resilience. Yampolskiy is attending the WEF Annual Meeting in Davos to engage with the world’s foremost public- and private-sector leaders on mitigating global cyber risk, including within critical infrastructure.
Critical Manufacturing Patching Cadence Falls Amid Escalating Attack Cadence
Cyber incidents affecting critical infrastructure, once comparatively rare, have become far more frequent in recent years as nation-states and their proxies escalate their pursuit of geopolitical objectives. Data from the Federal Bureau of Investigation showed that 14 of the 16 sectors considered critical infrastructure by the U.S. government experienced at least one ransomware attack in 2021.
SecurityScorecard assessed these industries to measure their current state of cyber resilience. It found that critical manufacturing is highly vulnerable based on analysis of all organizations under that category in The Forbes Global 2000 list. SecurityScorecard considers 10 factors when developing an organization’s security rating. Of those 10, the patching cadence ‘factor’ for critical manufacturing experienced a significant drop from 2021 to 2022, moving from 88 (B) to 76 (C).
High and Medium-Severity CVEs Strain Resources
The decline in patching is likely due to an increased volume of vulnerabilities. Critical manufacturing experienced a 38% year-over-year increase in high severity vulnerabilities. In 2022 alone, 76% of critical manufacturing organizations have high and medium-severity CVEs.
These CVEs may, in some cases, facilitate ransomware groups’ targeting of organizations in the sector. Manufacturers experienced an increase in malware infections from 2021 to 2022. In 2022, 37% of critical manufacturing organizations had malware infections.
“While investing in more technology might seem burdensome to resource-constrained critical infrastructure operators, the reality is that cybersecurity ratings technology is extremely cost-effective, especially when you consider the catastrophic cost of a breach is $9.44 million on average for U.S. organizations,” continued Yampolskiy. “By leveraging security ratings, these organizations have a simple way to build resilience and make more informed decisions to strengthen their cyber defenses by confidently measuring risk and quantifying the trustworthiness of their partners, contractors, third-and fourth-party vendors, and supply chains.”
To view the full research paper, please visit: https://resources.securityscorecard.com/davos-2023/addressing-the-trust-deficit
About SecurityScorecard
Funded by world-class investors including Evolution Equity Partners, Silver Lake Waterman, Sequoia Capital, GV, Riverwood Capital, and others, SecurityScorecard is the global leader in cybersecurity ratings with more than 12 million companies continuously rated. Founded in 2013 by security and risk experts Dr. Aleksandr Yampolskiy and Sam Kassoumeh, SecurityScorecard's patented rating technology is used by over 30,000 organizations for enterprise risk management, third-party risk management, board reporting, due diligence, cyber insurance underwriting, and regulatory oversight. SecurityScorecard is the first cybersecurity ratings company to offer digital forensics and incident response services, providing a 360-degree approach to security prevention and response for its worldwide customer and partner base. SecurityScorecard continues to make the world a safer place by transforming the way companies understand, improve and communicate cybersecurity risk to their boards, employees and vendors. Every organization has the universal right to their trusted and transparent Instant SecurityScorecard rating. For more information, visit securityscorecard.com or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
